Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2022, representing a year-over-year increase of 25%[142]. - The company achieved a revenue of 1,026,628.82 million yuan in 2022, representing a year-on-year growth of 37.92%[30]. - The company reported a significant increase in revenue, reaching approximately 1.5 billion RMB, representing a year-over-year growth of 25%[10]. - The company provided a revenue guidance for 2023, expecting a growth rate of 20% to 25%[143]. - The company provided a positive outlook for 2023, projecting a revenue growth of 20% to 25% based on new product launches and market expansion strategies[10]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 25% year-over-year[132]. - The company reported a revenue increase of 25% year-over-year, reaching CNY 1.5 billion in 2022[135]. - The company achieved a total operating revenue for 2022 of ¥10,266,288,179.53, representing a 37.92% increase from ¥7,443,769,724.38 in 2021[58]. Profitability - The net profit attributable to shareholders for 2022 was ¥1,374,604,224.18, a decrease of 17.24% from ¥1,661,028,567.53 in 2021[14]. - The adjusted net profit attributable to shareholders was 183,427.10 million yuan, an increase of 25.46% compared to the previous year[30]. - The overall gross margin improved to 45%, up from 40% in the previous year, reflecting better operational efficiency and cost management[10]. - The gross margin for the main business reached 36.73%, up by 0.71 percentage points from the previous year[30]. - The gross profit margin for the scientific research and technology services sector improved slightly to 36.73%, up from 36.48% in the previous year[60]. Investment and R&D - Investment in R&D increased by 15%, totaling 300 million RMB, focusing on innovative drug development and advanced technologies[10]. - The R&D budget for 2023 is set at RMB 300 million, a 20% increase from the previous year[143]. - The company invested CNY 200 million in R&D for new technologies, focusing on advanced drug delivery systems[135]. - The company has established a comprehensive drug development service platform, focusing on small molecule research and development, and is expanding capabilities in large molecule and gene therapy services[91]. - The company is investing 150 million RMB in new technology for drug discovery to improve efficiency[132]. Market Expansion - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by 2025[10]. - The company aims to strengthen its international service platform to provide cross-disciplinary and cross-regional solutions for clients[23]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[143]. - The company is actively pursuing mergers and acquisitions to strengthen its portfolio, with a budget of 500 million RMB allocated for potential acquisitions in 2023[10]. - The company is planning to expand its market presence in Asia, targeting a 20% increase in market share by 2025[122]. Client and Customer Engagement - User data showed that the number of active clients increased by 30%, reaching a total of 1,200 clients in 2022[10]. - User data showed an increase in active users by 30% year-over-year, reaching 2 million active users by the end of 2022[143]. - The company introduced approximately 800 new clients in 2022, diversifying its customer base[30]. - Customer satisfaction ratings improved to 85%, reflecting a 5% increase from the previous year[143]. Strategic Partnerships and Acquisitions - A new strategic partnership was announced with a leading pharmaceutical company to enhance drug development capabilities and accelerate commercialization efforts[10]. - The company completed a strategic acquisition to enhance its research capabilities, which is expected to contribute an additional 4,920,000 in revenue[119]. - The company completed an acquisition of a biotech firm for CNY 500 million, enhancing its product pipeline[135]. - The company is exploring partnerships with international firms to enhance its global reach and innovation[142]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in its future development outlook[3]. - The company has implemented measures to control market, liquidity, credit, operational, and legal risks associated with its hedging activities[83]. - The company has established a management system for futures and derivatives trading, ensuring compliance with operational norms and risk control measures[83]. Governance and Compliance - The company emphasizes innovation and technology development, focusing on chemical and biological technology platforms to meet evolving R&D demands[54]. - The company has established a sound governance structure, with independent committees providing professional decision-making support to the board[108]. - The company has implemented a financial decision-making process in accordance with its articles of association, allowing for independent financial management[112]. - The company has not reported any significant changes in accounting policies or principles related to hedging activities compared to the previous reporting period[82]. Environmental Responsibility - The company has complied with various environmental protection laws and standards applicable to its operations[192]. - The company has received multiple environmental impact assessment approvals for its new drug research and development projects from 2010 to 2021[192]. - The company has a wastewater treatment project in Xi'an with a capacity of 120 tons/day, which received environmental impact report approval in August 2020[195]. - The company reported a total wastewater discharge of 10.088 tons for CODcr, with no exceedance of discharge standards[199]. Workforce and Talent Management - The company expanded its workforce to 19,481 employees by the end of 2022, with 89.35% in R&D, production technology, and clinical services[30]. - The number of R&D personnel grew by 29.36% to 17,406, with a slight decrease in the proportion of R&D personnel to total staff[66]. - The company has implemented a talent development platform, including internal training and partnerships with renowned institutions, to attract and cultivate top global talent[55]. - The company has established a comprehensive training program to enhance employee skills and align personal development with corporate strategy[160]. Financial Management - The company has established a robust internal control and audit system to monitor financial activities and identify risks[185]. - The company has enhanced its financial reporting and tax management systems, improving efficiency and accuracy in financial forecasting and tax risk assessment[181]. - The company has integrated its subsidiaries into a unified management system, ensuring accurate consolidated financial reporting and operational efficiency[184]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management in 2022 amounted to CNY 1,339.22 million[148].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2022年12月31日止年度全年業績公告 財務摘要及要點 截至12月31日止年度 2022年 2021年 變動 人民幣千元 人民幣千元 % 收益 10,266,288 7,443,770 37.9 毛利 3,749,276 2,672,044 40.3 母公司擁有人應佔利潤 1,374,604 1,661,029 (17.2) 母公司擁有人應佔非國際財務報告 準則經調整淨利潤 1,834,271 1,461,985 25.5 經營活動所得現金流量淨額 2,142,816 2,058,044 4.1 － 於報告期間，本集團錄得總收益約人民幣10,266.3百萬元，較截至2021年 12月31日止年度增加約人民幣2,822.5百萬元或37.9% ...

Revenue and Profitability - Total revenue for Q3 2022 reached CNY 2,768,208,563.01, an increase of 37.31% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 20.95% to CNY 375,674,760.35 for Q3 2022[4] - Operating revenue increased to ¥7,402,793,998.96, a year-on-year growth of 39.63% compared to ¥5,301,532,904.44[8] - Total revenue for the nine months ended September 30, 2022, was RMB 7,402,794 thousand, an increase from RMB 5,301,533 thousand in the same period of 2021, representing a growth of 32.5%[46] - Net profit for the current period is 944,178,254.54, down from 1,003,928,223.19 in the previous period, indicating a decrease of approximately 5.9%[35] - The company reported a profit attributable to equity holders of RMB 961,107 thousand for the nine months ended September 30, 2022, down from RMB 1,040,063 thousand in 2021, indicating a decline of 7.6%[51] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY 1,395,070,031.14 for the year-to-date period, a decrease of 1.46% compared to the previous year[4] - Cash and cash equivalents decreased by 42.36% to ¥2,042,501,533.84 from ¥3,543,819,700.44, a reduction of ¥1,501,318,200[8] - Cash inflow from operating activities is 7,076,581,251.14, an increase from 5,410,437,911.75 in the previous period, reflecting a growth of approximately 30.8%[37] - Cash outflow from investment activities is 5,208,210,770.23, down from 7,505,559,923.92 in the previous period, indicating a reduction of approximately 30.5%[42] - Cash and cash equivalents decreased to RMB 1,780,290 thousand from RMB 3,526,577 thousand at the beginning of the year, indicating a decline of 49.5%[47] Assets and Liabilities - The total assets as of the end of Q3 2022 were CNY 19,706,904,963.16, reflecting a 7.17% increase from the end of the previous year[4] - Total liabilities increased to CNY 9,165,741,734.83 from CNY 8,093,817,609.58, marking a rise of 13.2%[26] - Total non-current assets increased to RMB 13,054,092 thousand as of September 30, 2022, up from RMB 9,745,622 thousand at the beginning of the year, marking a growth of 33.7%[47] - The company’s total assets less current liabilities amounted to RMB 16,060,504 thousand, an increase from RMB 15,407,128 thousand at the beginning of the year[47] Equity and Shareholder Information - The total equity attributable to shareholders was CNY 10,401,703,789.08, a 2.69% increase from the end of the previous year[4] - The total number of common shareholders at the end of the reporting period was 34,592[18] - The top ten shareholders collectively hold significant stakes, with HKSCC NOMINEES LIMITED owning 16.88% and Shenzhen Xinchongkang Investment Partnership holding 16.79%[19] Expenses and Cost Management - Total operating costs increased by 39.81% to ¥4,701,717,656.76 from ¥3,362,990,019.03, in line with revenue growth[14] - Sales expenses increased by 56.20% to ¥163,039,241.44 compared to ¥104,381,393.02 in the same period last year[15] - Management expenses rose by 73.19% to ¥1,036,265,811.81 from ¥598,348,091.85 year-on-year, primarily due to increased personnel costs and acquisitions[15] - R&D expenses grew by 61.55% to ¥177,468,493.98, up from ¥109,851,832.35, reflecting the company's commitment to enhancing R&D capabilities[15] Profit Margins and Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.3171, down 20.71% year-on-year[4] - The net profit excluding non-recurring gains and losses increased by 8.79% to CNY 377,837,497.51 for Q3 2022[4] - Basic earnings per share for the current period is 0.8118, down from 0.8754 in the previous period, representing a decrease of approximately 7.3%[36] Government Support and Subsidies - The company received government subsidies amounting to CNY 11,466,691.04 during the reporting period[6]

Financial Performance - The total revenue for the six months ended June 30, 2022, was approximately RMB 4,634.6 million, an increase of about RMB 1,349.1 million or 41.1% compared to the same period in 2021[8]. - The gross profit for the same period was RMB 1,613.1 million, reflecting a growth of 35.6% from RMB 1,189.7 million in the previous year[8]. - The profit attributable to equity holders of the parent company was approximately RMB 585.4 million, up by 3.6% from RMB 564.8 million in the prior year[9]. - The adjusted net profit for the period was RMB 812.1 million, representing a 24.7% increase from RMB 651.4 million in the previous year[9]. - The net cash flow from operating activities was approximately RMB 858.8 million, a slight increase of 1.6% compared to RMB 845.1 million in the same period last year[9]. - Basic earnings per share were approximately RMB 0.4941, up 4.0% from approximately RMB 0.4751 for the six months ended June 30, 2021[22]. - The company reported a profit of RMB 1,191,068,000 for the six months ending June 30, 2022, compared to RMB 794,177,000 for the same period in 2021, representing a year-over-year increase of approximately 50%[84]. - The total comprehensive income for the period was RMB 547,136,000, compared to RMB 564,837,000 in the previous period, indicating a slight decline[86]. Revenue Breakdown - Revenue from North American clients accounted for 65.6%, while European clients contributed 13.6%, and Chinese clients contributed 17.7%[11]. - The laboratory services segment generated revenue of RMB 2,860.1 million, a 41.1% increase year-on-year, with a gross margin of 43.4%[12]. - CMC (small molecule CDMO) services achieved revenue of RMB 1,084.6 million, a year-on-year increase of 42.3%, with a gross margin of 32.9%, down 3.6 percentage points from the previous year[13]. - Clinical research services generated revenue of RMB 584.5 million, up 38.3% year-on-year, with a gross margin of 5.1%, down 9.0 percentage points from the previous year[14]. - The company’s large molecule and cell and gene therapy services reported revenue of RMB 95.5 million, a 33.2% increase year-on-year, but with a gross margin of -19.8% due to high operational costs[16]. Operational Highlights - The company introduced over 400 new clients in the first half of 2022, expanding its customer base significantly[11]. - The company operates in China, the United States, and the United Kingdom, employing over 17,000 staff[6]. - The company has over 800 ongoing clinical trial projects and collaborates with more than 600 hospitals and clinical trial centers across 140 cities in China[15]. - The company has established a comprehensive chemical technology platform that covers the entire process of small molecule drug research, development, and production, enhancing its competitive advantage in the pharmaceutical R&D service market[31]. - The company has strengthened its integrated service platform through international acquisitions, enhancing service capabilities and R&D efficiency, exemplified by the acquisition of a production base in Cramlington, UK[35]. Strategic Initiatives - The company aims to accelerate drug innovation and become a global leader in multi-therapy drug development services[10]. - The company is focused on enhancing its service platform's synergy through vertical and horizontal integration in drug development[10]. - The company has committed to the Science Based Targets initiative (SBTi) to align its carbon reduction goals with international climate agreements[12]. - The company aims to enhance its integrated drug development service platform, focusing on small molecule research while accelerating the development of large molecule and cell/gene therapy services[40]. - The company plans to expand its laboratory chemistry capabilities and strengthen its CDMO services in small molecules, with a strategic focus on technology investment and service content expansion[41]. Acquisitions and Investments - The company acquired 100% equity of Beijing Ankai Yibo Biotechnology Co., Ltd. to enhance its capabilities in drug safety evaluation and biological sciences[13]. - The acquisition of Aesica Pharmaceuticals Limited was completed in January 2022 for approximately GBP 55 million (about RMB 473.35 million), enhancing the company's CDMO service platform[26]. - Pharmaron Manufacturing Services (US) LLC acquired the Coventry API production facility in Rhode Island for approximately $31.5 million (RMB 210.6 million), completed on July 1, 2022[78]. - The company completed the acquisition of Pharmaron Manufacturing Services (UK) Ltd for a cash consideration of GBP 58,052,000 (approximately RMB 500,837,000) on January 7, 2022[154]. Market Outlook - The global pharmaceutical market's R&D and production investment was approximately $566.1 billion in 2021, projected to reach $726.1 billion by 2026, with a CAGR of 6.5%[37]. - The Chinese pharmaceutical market's R&D and production investment was about RMB 562 billion in 2021, expected to grow to RMB 956.6 billion by 2026, reflecting a CAGR of 11.2%[37]. - The global pharmaceutical R&D and production outsourcing service market was valued at approximately $140.3 billion in 2021, anticipated to reach $247.7 billion by 2026, with a CAGR of 12%[37]. - The company aims to leverage its international operational experience to provide customized services and solutions in gene and cell therapy development[34]. Risk Management - The company faces potential risks, including a decline in demand for drug development services, which could lead to clients postponing project development or cutting research budgets, adversely affecting the company's performance and outlook[43]. - The company operates in a highly regulated environment, with strict legal and industry standards governing drug development and production, and must continuously meet regulatory requirements to avoid penalties or loss of operating qualifications[46]. - The company is committed to complying with increasingly stringent environmental regulations, which may increase compliance costs[47]. Corporate Governance - The company is committed to maintaining high standards of corporate governance to protect and enhance shareholder interests[49]. - The management team consists of experienced professionals, with over 30 years in the pharmaceutical industry, ensuring effective leadership and strategic direction for the company[35]. - The audit committee has reviewed the interim financial information and confirmed compliance with applicable accounting principles and sufficient disclosure[51].

康龙化成（北京）新药技术股份有限公司 2022 年半年度报告全文 康龙化成（北京）新药技术股份有限公司 Pharmaron Beijing Co., Ltd. （北京市北京经济技术开发区泰河路 6 号 1 幢八层） 2022 年半年度报告 公告编号：2022-073 2022 年 08 月 1 康龙化成（北京）新药技术股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 Boliang Lou、主管会计工作负责人李承宗及会计机构负责人 (会计主管人员)李承宗声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |--------------------------------------------------------------------------| | | | 报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 | | 对投资者的实质性承诺， ...

Financial Performance - In 2021, the company achieved revenue of RMB 7,443.8 million, a 45.0% increase compared to the previous year[8]. - The net profit attributable to shareholders was RMB 1,661.0 million, reflecting a growth of 41.7% year-on-year[8]. - The net cash flow from operating activities reached RMB 2,058.0 million, up 24.8% from the previous year[8]. - Total revenue for the year ended December 31, 2021, was approximately RMB 7,443.8 million, an increase of 45.0% compared to RMB 5,133.6 million for the year ended December 31, 2020[15]. - Gross profit for the year ended December 31, 2021, was approximately RMB 2,672.0 million, representing a 39.5% increase from RMB 1,916.1 million in 2020[15]. - Profit attributable to equity holders of the parent for the year ended December 31, 2021, was approximately RMB 1,661.0 million, up 41.7% from RMB 1,172.4 million in 2020[16]. - Net cash flow from operating activities for the year ended December 31, 2021, was approximately RMB 2,058.0 million, an increase of 24.8% compared to RMB 1,648.6 million in 2020[16]. - The company reported a diluted earnings per share of RMB 2.0537 for the year ended December 31, 2021, compared to RMB 1.4781 in 2020[17]. Asset and Equity Growth - By the end of 2021, total assets amounted to RMB 18,389.1 million, representing a 54.4% increase since the beginning of the year[8]. - The equity attributable to shareholders was RMB 10,129.2 million, which is a 14.2% increase from the start of the year[8]. - Total assets increased from RMB 4,143,664 thousand in 2017 to RMB 18,389,124 thousand in 2021, representing a growth of 343%[18]. - The equity attributable to the parent company grew from RMB 1,985,486 thousand in 2017 to RMB 10,129,241 thousand in 2021, marking a 410% increase[18]. - The leverage ratio improved significantly from 51.8% in 2017 to 44.0% in 2021, indicating a reduction in financial risk[18]. Client and Market Engagement - The company provided services to over 2,000 clients, including 800 new clients, and participated in 565 drug discovery projects in 2021[9]. - The company was involved in 77 domestic IND or NDA projects, with 56 projects submitted simultaneously in the US and other countries[9]. - In 2021, approximately 90% of the company's revenue came from a large, diverse, and loyal customer base, with 19.0% of revenue derived from the top 20 global pharmaceutical companies[29]. - Revenue from North American customers accounted for 64.2%, European customers (including the UK) contributed 15.6%, Chinese customers represented 17.1%, and other regions made up 3.1% of total revenue[29]. - The company introduced over 800 new customers in 2021, leading to a decrease in revenue concentration from the top 20 customers from 41.1% in 2020 to 33.8% in 2021[29]. Strategic Acquisitions and Expansion - The company expanded its international operations, acquiring Absorption Systems and Allergan Biologics Limited to enhance its capabilities in CGT services[11]. - The recent acquisition of a small molecule API commercialization facility in Cramlington, UK, aims to create a full industry chain service in chemical and production[11]. - The company plans to expand laboratory space in the UK and the US to meet growing business demands, including new laboratories in Boston and expansions in San Diego and Exton[12]. - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately GBP 55 million (about RMB 47.3 million), enhancing its small molecule CDMO service platform[40]. - The company acquired 100% equity in Zhongke Lingrui (Zhanjiang) Biotechnology Co., Ltd. for RMB 205.7 million, which has become a wholly-owned subsidiary[39]. Research and Development Focus - The company is focused on enhancing its capabilities in large molecule drugs and cell and gene therapy, aiming to become a global leader in multi-therapy drug development services[23]. - The company plans to launch a new CDMO platform for large molecule drug development and production, with an expected capacity of 70,000 square meters to be operational in 2023[27]. - The company is expanding its clinical research services, integrating platforms for both domestic and international clinical trials[27]. - The company is enhancing its capabilities in gene therapy and cell therapy, including the development of various analytical methods for DNA and RNA[28]. - The company is committed to providing high-level R&D services to assist partners in successfully developing new drugs, contributing to life sciences[19]. Sustainability and ESG Initiatives - The company has set sustainable development goals for 2021-2025, improving its ESG rating from BB in 2020 to BBB in 2021[13]. - The management team emphasized a focus on sustainability initiatives, aiming for a 15% reduction in carbon emissions by 2025[46]. - The company emphasizes environmental protection, health, safety, and intellectual property rights, ensuring robust protection for client IP, which has garnered widespread recognition and trust[51]. Corporate Governance and Management - The board proposed a final cash dividend of RMB 4.5 per share for the year ended December 31, 2021, totaling approximately RMB 357.4 million[16]. - The board of directors is committed to maintaining high levels of corporate governance, which is crucial for the group's development and safeguarding shareholder interests[85]. - The company has adhered to the corporate governance code during the relevant period from January 1, 2021, to December 31, 2021[85]. - The board consists of 11 members, including 9 males and 2 females, with diverse educational backgrounds and skills in various fields such as chemistry, business management, and law[87]. - The company emphasizes the importance of board diversity, considering factors like gender, age, and professional experience in its appointments[86]. Risk Management and Compliance - The company has established a risk management system aimed at improving risk prevention capabilities and promoting sustainable development[111]. - The internal audit system is designed to enhance the quality and efficiency of internal audits and improve the company's supervision and risk control mechanisms[111]. - The company has implemented a tiered management approach for comprehensive risk management, involving the board of directors, audit committee, and various functional departments[112]. - The company has conducted eight meetings of the supervisory board as of the report date[108]. - The company has established early warning and emergency response mechanisms to manage major risks and unexpected events[111]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to 1.44 billion[46]. - The company plans to increase its workforce by 10% to support growth initiatives[46]. - The company aims to enhance shareholder value through a share buyback program, allocating 50 million for this initiative in 2022[73]. - The company plans to implement strategic market strategies tailored to the characteristics of the Chinese market to accumulate customer resources and enhance competitiveness[57]. - The company recognizes the risk of a potential decline in demand for drug development services, which could adversely affect operational performance if the global pharmaceutical market growth slows[58].

Financial Performance - The company's revenue for Q1 2022 was CNY 2,102,899,933.93, representing a 41.19% increase compared to CNY 1,489,385,309.64 in the same period last year[4]. - Net profit attributable to shareholders was CNY 249,086,573.60, a slight increase of 1.31% from CNY 245,874,010.35 year-on-year[4]. - The net profit excluding non-recurring gains and losses was CNY 310,563,849.47, reflecting a 30.83% increase from CNY 237,376,010.22 in the previous year[4]. - Operating revenue for the reporting period reached ¥2,102,899,933.93, an increase of 41.19% compared to ¥1,489,385,309.64 in the same period last year[9]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥310,563,849.47, reflecting a growth of 30.83% from ¥237,376,010.22 year-on-year[9]. - The company reported a total profit of $316.18 million, compared to $282.48 million in the previous period, marking an increase of 11.96%[34]. - The adjusted net profit attributable to the parent company for the first quarter of 2022 was RMB 364,396 thousand, a significant increase of 39.1% year-over-year[47]. Cash Flow and Assets - The company's cash flow from operating activities was CNY 417,792,056.81, down 16.27% from CNY 498,953,761.05 in the same quarter last year[4]. - The total assets at the end of the reporting period were CNY 18,660,920,785.51, a 1.48% increase from CNY 18,389,124,353.35 at the end of the previous year[4]. - The company has shown a strong increase in cash and cash equivalents, with current assets totaling CNY 7,646,204,942.02, down from CNY 8,643,502,127.97, indicating a decrease of about 11.5%[22]. - The company’s cash and cash equivalents were RMB 2,873,493 thousand as of March 31, 2022, down from RMB 3,526,577 thousand at the end of 2021, indicating a decrease of about 18.5%[43]. Expenses and Liabilities - The company's cash flow from financing activities is -$298.11 million, a decrease from $285.02 million in the previous period, indicating a decline of 204.73%[41]. - Operating costs increased by 44.77% to ¥1,407,271,726.88, aligning with the revenue growth[10]. - The company reported a significant rise in financial expenses, up 416.87% to ¥40,234,145.81, primarily due to increased interest expenses[11]. - Total liabilities increased to CNY 8,316,165,204.05 from CNY 8,093,817,609.58, reflecting a rise of approximately 2.8%[26]. Shareholder Information - The top ten shareholders hold a combined 66.77% of the company's shares, with the largest shareholder owning 18.68%[12]. - The top ten unrestricted shareholders hold a total of 448,000,000 shares, with Shenzhen Xinchongkang Investment Partnership holding the largest share of 148,335,300 shares[14]. - The company’s major shareholders include individuals with significant connections, such as Mr. Lou Xiaoqiang, who holds 100% of Ningbo Longtai Kang Investment Management Co., Ltd.[15]. Research and Development - Research and development expenses increased by 36.27% to ¥39,647,299.50 from ¥29,095,136.05 year-on-year, indicating a commitment to enhancing R&D capabilities[11]. - The company reported a net investment loss of CNY 7,402,982.10 from joint ventures and associates, compared to a loss of CNY 344,610.97 in the previous period[77]. Acquisitions and Integrations - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately £55 million (around RMB 47.34 million), enhancing its CDMO service capabilities[18]. - The integration of clinical research services through Kanglong Chemical (Chengdu) Clinical Research Service Co., Ltd. aims to optimize clinical R&D capabilities and improve service quality[19]. Government Support - The company received government subsidies amounting to CNY 9,391,153.38 during the reporting period[6].